- Home
- IMNN vs CRIS Comparison
IMNN vs CRIS Comparison
Compare IMNN & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMNN | CRIS |
|---|---|---|
| Founded | 1982 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 12.9M |
| IPO Year | 1985 | 2000 |
Fundamental Metrics
Financial Performance| Metric | IMNN | CRIS |
|---|---|---|
| Price | $3.25 | $1.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $182.61 | $16.50 |
| AVG Volume (30 Days) | 36.3K | ★ 264.0K |
| Earning Date | 03-27-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $11,650,000.00 |
| Revenue This Year | N/A | $6.13 |
| Revenue Next Year | N/A | $7.86 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.56 |
| 52 Week Low | $2.99 | $0.77 |
| 52 Week High | $41.22 | $3.41 |
Technical Indicators
Market Signals| Indicator | IMNN | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 42.61 | 64.19 |
| Support Level | $3.03 | $0.95 |
| Resistance Level | $3.62 | $0.96 |
| Average True Range (ATR) | 0.24 | 0.09 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 25.57 | 84.50 |
Price Performance
Historical ComparisonAbout IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.